Y-mAbs Therapeutics (NASDAQ: YMAB) reported Friday that its cancer drug naxitamab demonstrated consistent disease control in refractory or relapsed high-risk, or hard-to-treat neuroblastoma cancer patients.
The company said naxitamab, combined with granulocyte-macrophage colony-stimulating factor, achieved a 63% disease control rate in patients with refractory or relapsed high-risk neuroblastoma, regardless of their baseline condition.
Y-mAbs also unveiled preclinical findings for its GD2-SADA therapy, which showed potential of delivering targeted radiation to cancer cells.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments